References
- Cornberg M, Razavi HA, Alberti A et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 31(Suppl. 2), 30–60 (2011).
- Himoto T, Masaki T. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin. Dev. Immunol. 2012, 871401 (2012).
- Abenavoli L, Almasio PL. Chronic hepatitis C infection and insulin resistance: two best friends. Expert Rev. Anti. Infect. Ther. 9(8), 555–558 (2011).
- Rouabhia S, Malek R, Bounecer H et al. Prevalence of Type 2 diabetes in Algerian patients with hepatitis C virus infection. World J. Gastroenterol. 16(27), 3427–3431 (2010).
- Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J. Gastroenterol. 12(42), 6756–6765 (2006).
- White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J. Hepatol. 49(5), 831–844 (2008).
- Arrese M, Riquelme A, Soza A. Insulin resistance, hepatic steatosis and hepatitis C: a complex relationship with relevant clinical implications. Ann. Hepatol. 9(Suppl.), 112–118 (2010).
- Petta S, Cammà C, Di Marco V et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int. 31(4), 507–515 (2011).
- Leandro G, Mangia A, Hui J et al.; HCV Meta-Analysis (on) Individual Patients’ Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130(6), 1636–1642 (2006).
- Eslam M, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Use of HOMA-IR in hepatitis C. J. Viral Hepat. 18(10), 675–684 (2011).
- Brenner DA, Kisseleva T, Scholten D et al. Origin of myofibroblasts in liver fibrosis. Fibrogenesis Tissue Repair 5(Suppl. 1), S17 (2012).
- Negro F. Steatosis and insulin resistance in response to treatment of chronic hepatitis C. J. Viral Hepat. 19(Suppl. 1), 42–47 (2012).
- Sanyal AJ. Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C. Liver Int. 31(Suppl. 1), 23–28 (2011).
- Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon α-2a plus ribavirin. Hepatology 56(2), 464–473 (2012).
- Walsh MJ, Jonsson JR, Richardson MM et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 55(4), 529–535 (2006).
- Miyaaki H, Ichikawa T, Nakao K et al. Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C. Hepatol. Res. 39(9), 850–855 (2009).
- Khattab M, Emad M, Abdelaleem A et al. Pioglitazone improves virological response to peginterferon α-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int. 30(3), 447–454 (2010).
- Chojkier M, Elkhayat H, Sabry D, Donohue M, Buck M. Pioglitazone decreases hepatitis C viral load in overweight, treatment naive, genotype 4 infected-patients: a pilot study. PLoS ONE 7(3), e31516 (2012).
- Romero-Gómez M, Diago M, Andrade RJ et al.; Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 50(6), 1702–1708 (2009).
- Serfaty L, Forns X, Goeser T et al. Insulin resistance and response to telaprevir plus peginterferon a and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut 61(10), 1473–1480 (2012).